Effectiveness of Pentoxifylline in the treatment of oral submucous fibrosis patients: a case-control study

Springer Science and Business Media LLC - Tập 39 Số 1 - 2019
Annette M. Bhambal1, Ajay Bhambal1, Uma Shankar Shukla2, Aashna Dhingra1
1Department of Public Health Dentistry, People’s College of Dental Sciences and Research Centre, Bhopal, Madhya Pradesh, India
2Department of Community Medicine, Government Jhalawar Medical College, Jhalawar, Rajasthan, India

Tóm tắt

Abstract Background Oral submucous fibrosis (OSMF) is a potentially malignant disorder largely seen in the South-Asian countries where areca nut is found to be the main predisposing factor. Pentoxifylline, a methylxanthine derivative, has vasodilating properties and is believed to increase the vascularity of the mucosal layer. This study was designed to determine the effect of pentoxifylline (Trental) on the clinical progression of oral submucous fibrosis. Aim: The present study was aimed to evaluate the effectiveness of drug pentoxifylline in the management of OSMF and to correlate the clinical parameters evaluated before and after treatment. Methods Study Design: This investigation was conducted as a case-control study incorporating a Control Group in comparison to a Study Group where pentoxifylline 400 mg was administered 3 times daily, as coated, sustained-release tablets for prescribed for 3 months. The stipulated period for the study was 8 months and a total of 80 cases of oral submucous fibrosis (40 test subjects and 40 controls) were included in this study and 100% acquiescence was reported at the end of the test period. Results Mild dizziness and gastric irritation were the only untoward symptoms reported in 2 of the volunteers in the study group during this trial. These were managed by diet protocols. A review of the patients and controls was done at an interval of every 4 weeks for 3 months. The subjective and objective measurements were recorded. The follow-up data at each visit concerning each other and to base-line values were calibrated using nonparametric tests of the Chi-Square test and Mann-Whitney. Significant comparisons with regard to improvement were recorded as objective criteria of mouth opening (u value =1.137, p = 0.260), tongue protrusion (u value = 0.262, p = 0.794 and cheek flexibility (u value =0.990, p = 0.326). Subjective symptoms of burning sensation of mouth (U value = 2.673, p = 0.008), pain on opening the mouth (U value = 4.320, p < 0.0001), difficulty in swallowing and difficulty in the speech were also recorded. Conclusion This study showed the effectiveness of pentoxifylline as an additional therapy in the routine management of oral submucous fibrosis.

Từ khóa


Tài liệu tham khảo

Gupta J, Srinivasan SV, Daniel MJ. Efficacy of betamethasone, placental extract and Hyaluronidase in the treatment of OSMF: a comparative study. E-Journal of Dentistry. 2012;2:132–5.

Aara A, Satishkumar GP, Vani C, Venkat Reddy M, Sreekanth K, Ibrahim M. Comparative study of Intralesional dexamethasone, Hyaluronidase and Oral Pentoxifylline in patients with Oral submucous fibrosis. Global J Med Res. 2012;12(7):169–73.

Bailoor D, John A, Koteeshwaran D, Parekh BP, White lesions of oral mucosa. In: Bailoor D, Nagesh KS, editors. Fundamentals of oral medicine and radiology. 1st ed. New Delhi: Jaypee Brothers Medical Publishers (P) ltd; 2005. p. 117–33.

Mehrotra R, Singh HP, Gupta SC, Singh M, Jain S. Pentoxifylline therapy in the management of oral submucous fibrosis. Asian Pac J Cancer Prev. 2011;12:971–4.

Ali FM, et al. Oral submucous fibrosis: comparing clinical grading with duration and frequency of habit among areca nut and its products chewers. J Cancer Res Ther. 2013;9(3):471–6.

Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis. Journal of Orofacial. Sciences. 2014;6(2):94–98.

Rajendran R, Vijayakumar T, Vasudevan DM. An alternative pathogenetic pathway for oral submucous fibrosis. Med Hypothesis. 1989;30:35–7.

Rajendran R, Rani V, Shaikh S. (2006). Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J of Dent Res. 2006;17(4):190–8.

Prabhu N, Rao SS, Kotrashetti SM, Baliga SD, Hallikerimath SR, Angadi PV, Issrani R. (2015). Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial. J. Maxillofac. Oral Surg. 2015;14(1):81–9.

Liu J, Chen F, Wei Z, Qiu M, Li Z, Dan H, Chen Q, Jiang L. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: a meta-analysis. Oral Diseases 2018. 2018;24(5):706–16.

Kalkur C, Sattur AP, Guttal KS, Lakshman AR. “Introducing modified Dakkak and Bennett grading system for Indian food in Oral submucous fibrosis”: a Dharwad study. J Diet Suppl. 2019;16(2):207–14.

Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drug Eval. 1987;34:50–97.

Berman B, Dunken MR. Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycans, and fibronectin production, and increases collagenase activity. J Invest Dermatol. 1989;92:605–10.

Berman B, Wietzerbin J, Sangean J, et al. Pentoxifylline inhibits certain constitutive and tumor necrosis factor-a induced activities of human normal dermal fibroblasts. J Invest Dermatol. 1992;98:706–12.

Edwards MJ, Abney DL, Miller FN. Pentoxifylline inhibits interleukin-2 induced leukocyte-endothelial adherence and reduces systemic toxicity. Surg. 1991;110:199–204.

Fedorowicz Z. Chan Shih- yen E, Dorri M, Nasser M, Newton T, Shi L. (2008) interventions for the management of oral submucous fibrosis. Cochrane Database Syst Rev. 2008;4:CD007156.

Mulk BS, Deshpande PS, Velpula N, Chappidi V, Chintamaneni RL, Goyal S. (2013). Spirulina and pentoxyfilline- a novel approach for treatment of oral submucous fibrosis. J Clin Diagn Res. 2013;7(12):3048–50.

Awadallah M, Idle M, Patel K, Kademani D. Management update of potentially premalignant Oral epithelial lesions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:628–36.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 39 Số 1

Thông tin tác giả